These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 7788426)
1. Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia. White A; LaFon S; Rogers M; Andrews E; Brown N J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):280-5. PubMed ID: 7788426 [TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703 [TBL] [Abstract][Full Text] [Related]
3. Treatment IND protocol announced for Pneumocystis carinii pneumonia. Clin Pharm; 1992 Feb; 11(2):99, 103. PubMed ID: 1551304 [No Abstract] [Full Text] [Related]
4. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489 [TBL] [Abstract][Full Text] [Related]
5. Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients. Dohn MN; Frame PT; Baughman RP; Lafon SW; Smulian AG; Caldwell P; Rogers MD J Protozool; 1991; 38(6):220S-221S. PubMed ID: 1818178 [TBL] [Abstract][Full Text] [Related]
6. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ; Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703 [TBL] [Abstract][Full Text] [Related]
7. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851 [TBL] [Abstract][Full Text] [Related]
8. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944 [TBL] [Abstract][Full Text] [Related]
9. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. Falloon J; Kovacs J; Hughes W; O'Neill D; Polis M; Davey RT; Rogers M; LaFon S; Feuerstein I; Lancaster D N Engl J Med; 1991 Nov; 325(22):1534-8. PubMed ID: 1944437 [TBL] [Abstract][Full Text] [Related]
10. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Meyers B; Borrego F; Papanicolaou G Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024 [TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. Kazanjian P; Armstrong W; Hossler PA; Lee CH; Huang L; Beard CB; Carter J; Crane L; Duchin J; Burman W; Richardson J; Meshnick SR J Infect Dis; 2001 Mar; 183(5):819-22. PubMed ID: 11181161 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC Semin Respir Infect; 1997 Jun; 12(2):79-97. PubMed ID: 9195673 [TBL] [Abstract][Full Text] [Related]
14. Atovaquone: a new antipneumocystis agent. Artymowicz RJ; James VE Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520 [TBL] [Abstract][Full Text] [Related]
15. Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia. Epstein LJ; Mohsenifar Z; Daar ES; Yeh V; Meyer RD Am J Med Sci; 1994 Jul; 308(1):5-8. PubMed ID: 8010339 [TBL] [Abstract][Full Text] [Related]
16. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228 [TBL] [Abstract][Full Text] [Related]
18. [Therapy and prevention of pneumocystis carinii pneumonia]. Goebel FD; Bogner JR Internist (Berl); 1995 Dec; 36(12):1150-5. PubMed ID: 8567220 [No Abstract] [Full Text] [Related]
19. Prophylaxis and therapy for Pneumocystis pneumonia--where are we? Masur H Infect Agents Dis; 1992 Oct; 1(5):270-8. PubMed ID: 1344666 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Bennett CL; Oddone E; Matchar D Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]